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Abstract
Background: Human milk provides necessary macronutrients (protein, carbohydrate, fat) required for infant
nutrition. Lactoferrin (Lf), a multifunctional iron-binding protein predominant in human milk, shares similar protein
sequence, structure, and bioactivity with bovine Lf (bLf). This large-scale pediatric nutrition study was designed to
evaluate growth and tolerance in healthy infants who received study formulas with bLf at concentrations within
the range of mature human milk.
Methods: In this multi-center, double-blind, parallel-designed, gender-stratified prospective study 480 infants were
randomized to receive a marketed routine cow’s milk-based infant formula (Control; n = 155) or one of two
investigational formulas with bLf at 0.6 g/L (LF-0.6; n = 165) or 1.0 g/L (LF-1.0; n = 160) from 14–365 days of age.
Investigational formulas also had a prebiotic blend of polydextrose (PDX) and galactooligosaccharides (GOS) and
adjusted arachidonic acid (ARA). The primary outcome was weight growth rate from 14–120 days of age.
Anthropometric measurements were taken at 14, 30, 60, 90, 120, 180, 275, and 365 days of age. Parental recall of
formula intake, tolerance, and stool characteristics was collected at each time point. Medically-confirmed adverse
events were collected throughout the study period.
Results: There were no group differences in growth rate (g/day) from 14–120 days of age; 353 infants completed
the study through 365 days of age (Control: 110; LF-0.6: 127; LF-1.0: 116). Few differences in growth, formula intake,
and infant fussiness or gassiness were observed through 365 day of age. Group discontinuation rates and the
overall group incidence of medically-confirmed adverse events were not significantly different. From 30 through
180 days of age, group differences in stool consistency (P < 0.005) were detected with softer stools for infants in the
LF-0.6 and LF-1.0 groups versus Control.
Conclusion: Compared to the Control, infants who received investigational formulas with bLf and the prebiotic
blend of PDX and GOS experienced a softer stooling pattern similar to that reported in breastfed infants. This study
demonstrated routine infant formulas with bLf, a blend of PDX and GOS, and adjusted ARA were safe, well-tolerated,
and associated with normal growth when fed to healthy term infants through 365 days of age.
Trial registration: ClinicalTrials.gov NCT01122654. Registered 10 May 2010.
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Background
Human milk provides the necessary protein, carbohydrate,
and fat macronutrients required for infant nutritional
needs. The protein component of cow’s milk-based infant
formula is often patterned after mature human milk in
which the ratio of whey and casein varies throughout
lactation [1]. Lactoferrin (Lf ), a multifunctional iron-
binding protein predominant in the whey fraction
(range, mature human milk: 0.44-4.4 g/L [2]), is in-
volved in cellular proliferation and differentiation, iron
status maintenance, host defense against microbial in-
fection, anti-inflammatory activity and immune modula-
tory effects, and acts as a transcription factor (reviewed in
[3]). Lf is synthesized by epithelial cells of the mammary
glands and also present in other exocrine fluids [4]. Hu-
man Lf and bovine Lf (bLf) proteins share ~70 % se-
quence homology, are structurally similar, and in both in
vitro and animal models have demonstrated comparable
bioactivity (reviewed in [5]). Lf resists proteolysis in the in-
fant gastrointestinal tract and uptake of both Lf and bLf
has been demonstrated in vitro using an intestinal entero-
cyte model (reviewed in [3]). Minor amounts of bLF
(≈30–485 mg/L) are available in cow’s milk [6], and there-
fore scarce in cow’s milk-based infant formula. A previous
pilot study in healthy term infants demonstrated that
addition of bLf (850 mg/L) to infant formula was well-
tolerated, safe, and associated with a lower incidence of re-
spiratory tract infections [7]. In children, dietary bLf low-
ered parasite colonization (1 g/day) [8] and reduced
frequency and duration of vomiting and diarrhea (100
mg/day) [9]. Growth, safety, and a decrease in invasive
fungal infections have been demonstrated in preterm in-
fants who received bLf (100 mg/day) [10].
Human milk oligosaccharides (HMOs) are carbohy-
drates that comprise the third largest component in hu-
man milk (mature milk range, 5–15 g/L) following
lactose and fat [11]. Over one hundred distinct HMOs
have been identified, with composition differing between
women and stage of lactation, which serve as a growth
substrate for beneficial bacteria, inhibit pathogen adher-
ence due to anti-adhesive properties, and modulate
immune and intestinal epithelial cell responses [11]. Pre-
biotics, often used in infant formula to simulate the
functionality of HMOs, are defined as “a selectively fer-
mented ingredient that allows specific changes, both in
the composition and/or activity in the gastrointestinal
microbiota that confers benefits upon host well-being
and health” [12]. Softer, looser stools are characteristic
of both breastfed infants and infants who receive for-
mula with (vs without) prebiotics [13–15]. In healthy
term infants we previously demonstrated that cow’s
milk-based infant formula with a prebiotic blend of
polydextrose (PDX) and galactooligosacccharides (GOS)
(1:1 ratio, 4 g/L) was well-tolerated, supported normal
growth, promoted a stool consistency closer to that of
breastfed infants [16] and produced a bifidogenic effect
[17] and softer stools [16–19] when compared to infants
who received a formula without PDX and GOS. This
blend of PDX (mixture of complex, slowly fermented
polysaccharides) and GOS (mixture of rapidly fermented
oligosaccharides) covers the molecular weight range of
most HMOs and meets the definition of a prebiotic used
by the European Society for Paediatric Gastroenterology
Hepatology and Nutrition (ESPGHAN) and the Food
and Agriculture Organization of the United Nations
(FAO) [20, 21].
The present study was designed to evaluate growth
and tolerance in healthy term infants receiving infant
formulas with bLf at 0.6 and 1.0 g/L with weight growth
rate from 14–120 days of age as the primary outcome.
Concentrations used for bLf were within the reported
range for Lf in mature human milk. In addition, investi-
gational formulas included the prebiotic PDX and GOS
blend (4 g/L) as well as an adjustment in arachidonic
acid (ARA) based on updated worldwide means for hu-
man milk docosahexaenoic acid (DHA) and ARA [22].
However, infant formulas may be provided up to 12
months of age even as complementary foods begin to be
introduced. For this reason, we also assessed growth, tol-
erance, and adverse events for participants from 14 to
approximately 365 days of age to assess the use of study
formulas throughout the first year of life.
Methods
Study population
Healthy 12- to 16-day-old infants were recruited at 24
clinical sites in the United States. Eligible infants were
singleton births at 37–42 weeks gestational age with
birth weight ≥ 2500 g and solely formula-fed at least 24
h prior to randomization. Exclusion criteria included
history of underlying disease or congenital malformation
likely to interfere with normal growth and development
or participant evaluation; signs of acute infection includ-
ing fever, diarrhea, or antibiotic use; feeding difficulties
or formula intolerance; weight at randomization <98 %
of birth weight; large for gestational age born from a
mother diabetic at childbirth; and immunodeficiency.
Study design
In this multicenter, double-blind, randomized, con-
trolled, parallel-group, prospective trial, participants
were enrolled between July 2010 and January 2011. The
study sponsor created a computer-generated, gender-
stratified randomization schedule provided in sealed
consecutively-numbered envelopes for each study site.
Study formula was assigned by opening the next sequen-
tial envelope from the appropriate set at the study site.
Study formulas, each designated by two unique codes
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known only to the sponsor, were dispensed to parents at
each study visit prior to study completion or withdrawal.
Participants were randomly assigned to receive one of
three study formulas (isocaloric, 20 calories/fluid oz): a
routine cow’s milk-based infant formula (Control; mar-
keted Enfamil®, Mead Johnson Nutrition, Evansville, IN)
or one of two investigational formulas with bLf (DMV
International bv) at 0.6 g/L (LF-0.6) or 1.0 g/L (LF-1.0)
from 14 days of age up to 365 days of age (Table 1). All
study formulas provided DHA at 17 mg/100 kcal. ARA
was provided at 34 mg/100 kcal in the Control and 25
mg/100 kcal in the investigational formulas. Each inves-
tigational formula also had 4 g/L (1:1 ratio) of a blend of
PDX (Litesse® Two Polydextrose; Danisco) and GOS
(Vivinal® GOS Galactooligosaccharide; Friesland Foods
Domo).
Ethics
Parents or guardians provided written informed consent
prior to enrollment. The research protocol and informed
consent forms observing the Declaration of Helsinki (in-
cluding October 1996 amendment) were approved by
the New England Institutional Review Board (IRB; New-
ton, MA); the University of Nebraska Medical Center,
IRB, Office of Regulatory Affairs (Omaha, NE); Western
IRB (Olympia, WA); and the University of Louisville IRB
(Louisville, KY). The study complied with good clinical
practices.
Study objectives and outcomes
Anthropometric measures (body weight, length, and
head circumference) were recorded at 14, 30, 60, 90,
120, 180, 275, and 365 days of age. At study enrollment,
parents completed a baseline recall of tolerance (fussi-
ness and gassiness), and stool characteristics (frequency
and consistency) and provided information on partici-
pant’s history of breastfeeding (0, ≤7, or >7 days prior to
study enrollment), family history of allergy in one or
more relatives (including biological mother, father, sib-
ling, and/or half-sibling) and exposure to smoking in the
home. At all subsequent study visits, information on en-
rollment in daycare, exposure to smoking in the home
and/or daycare, and 24-h recall of formula intake (fluid
oz/day), tolerance (fussiness and gassiness), and stool
characteristics (frequency and consistency) was col-
lected. Responses were scaled from 0–3 for amount of
gas (none, slight amount, moderate amount, excessive
amount); 0–4 for fussiness (not fussy, slightly fussy,
moderately fussy, very fussy, extremely fussy); and 1–5
for stool consistency (hard, formed, soft, unformed or
seedy, watery). The primary outcome was weight growth
rate from 14–120 days of age. Secondary outcomes
included anthropometrics, tolerance measures, and
medically-confirmed adverse events through 365 days of
age. Adverse events were coded according to specific
event (e.g. otitis media, colic, etc.) and the body system
involved including: Body as a Whole; Cardiovascular;
Eye, Ears, Nose, and Throat; Endocrine; Gastrointestinal;
Metabolic and Nutrition; Musculoskeletal; Nervous; Re-
spiratory; Skin; and Urogenital. Participants received ex-
clusive study formula feeding through 120 days of age.
Participants who continued in the study through 365
days of age were considered to complete the study even
if study formula consumption discontinued or decreased
Table 1 Nutrient composition per 100 kcal (20 Calories/fluid oz)
Nutrient Study formula (target values)
Control LF-0.6 LF-1.0
Total Protein, g 2.1 2.1a 2.1b
Total Fat, g 5.3 5.3 5.3
ARA, mg 34 25 25
DHA, mg 17 17 17
Total Carbohydrate, g 10.9 11.2c 11.2c
Vitamin A, IU 300 300 300
Vitamin D, IU 60 60 60
Vitamin E, IU 2 2 2
Vitamin K, mcg 9 9 9
Thiamin, mcg 80 80 80
Riboflavin, mcg 140 140 140
Vitamin B6, mcg 60 60 60
Vitamin B12, mcg 0.3 0.3 0.3
Niacin, mcg 1000 1000 1000
Folic Acid, mcg 16 16 16
Pantothenic Acid, mcg 500 500 500
Biotin, mcg 3 3 3
Vitamin C, mg 12 12 12
Choline, mg 24 24 24
Inositol, mg 6 6 6
Calcium, mg 78 78 78
Phosphorus, mg 43 43 43
Magnesium, mg 8 8 8
Iron, mg 1.8 1.8 1.8
Zinc, mg 1 1 1
Manganese, mcg 15 15 15
Copper, mcg 75 75 75
Iodine, mcg 15 15 15
Selenium, mcg 2.8 2.8 2.8
Sodium, mg 27 27 27
Potassium, mg 108 108 108
Chloride, mg 63 63 63
awith bLF, 0.6 g/L
bwith bLF, 1.0 g/L
cwith prebiotic blend of PDX and GOS (4 g/L)
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to fewer than 2 feedings/day after 275 days of age (ap-
proximately 9-months-old).
Statistical methods
The sample size was chosen to detect a clinically rele-
vant difference of 3 g/day in weight gain from 14–120
days of age (80 % power; one-tailed). Assuming a stand-
ard deviation of 6 g/day for male and 5 g/day for female
participants, approximately 78 males and 55 females
were needed to enroll in each group with the expect-
ation that 51 male and 36 female participants per study
group would complete the study through 120 days of
age. Analysis of variance (ANOVA) was used to assess
growth rates in four pre-specified time intervals: from
14 to 30, 60, 90, or 120 days of age, calculated for each
participant by linear regression of weight on age. Mean
weight growth rates by gender for each investigational
formula group were compared with the Control using
one-tailed tests as outlined in guidance provided by the
American Academy of Pediatrics (AAP) Task Force on
Clinical Testing of Infant Formulas [23]. For all second-
ary outcomes, overall comparisons for the three formula
groups were two-tailed. Unadjusted pairwise compari-
sons were performed if the overall test was statistically
significant. All tests were conducted at α = 0.05.
Achieved weight, length, and head circumference; length
and head circumference growth rates; formula intake;
and stool frequency were analyzed by ANOVA. Stool
consistency, fussiness, and gas were analyzed using the
Cochran-Mantel-Haenszel (CMH) row mean score test.
Incidence of adverse events as well as incidence of aller-
gic manifestations, gastrointestinal infections, respiratory
infections, or any infection-related adverse events were
analyzed using Fisher’s exact test. All analyses were con-
ducted using SAS version 9.2 (Cary, NC).
Results
Participants
A total of 480 participants were enrolled and random-
ized (Control: 155; LF-0.6: 165; LF-1.0: 160). Participants
who were randomized but consumed no study formula
(Control: 1; LF-0.6: 1; LF-1.0: 2) were not included in
subsequent analyses (Fig. 1). No differences in body
weight, length, or head circumference were observed by
gender among groups at study enrollment (Table 2).
Birth anthropometric measures as well as gender, race,
and ethnic distribution, history of breastfeeding, family
history of allergy, and exposure to smoking in the home
were also similar among groups (data not shown). No
group differences from 30 to 365 days of age in daycare
enrollment and exposure to smoking in the home and/
or daycare were detected (data not shown). A total of
353 infants completed the study (Control: 110; LF-0.6:
127; LF-1.0: 116).
Growth
Growth rates were analyzed from 14–365 days of age.
As outlined in guidance provided by the AAP Task
Fig. 1 Flow of study participants
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Force on Clinical Testing of Infant Formulas, rate of
weight gain (g/day) is used as the most important param-
eter in clinical evaluation of infant formulas with differ-
ences of >3 g/day over a 3–4 month period considered
clinically significant [23]. Consequently, no statistically
significant group differences by gender in the primary out-
come, weight growth rate from day 14–120, were detected
(Table 3). No statistically significant differences were ob-
served for weight, length, or head circumference growth
rates by gender for any measured age range among study
groups with the exception of lower weight growth rate for
females in the LF-1.0 compared to the Control group from
day 14–60 (29.7 ± 0.9 vs 32.4 ± 1.0 g/day; P < 0.05). This
small difference within a single measured age range at less
than 3 g/day was not considered clinically significant. In
addition, no other statistically significant differences were
observed for mean achieved weight, length, or head cir-
cumference at any measured time point up to 365 days of
age. Mean achieved weight for males (Fig. 2) and females
(Fig. 3) plotted on the WHO weight-for-age standard
growth chart [24, 25] fell approximately within the 25th
and 75th percentiles at all study time points.
Tolerance
Parent-reported mean study formula intake (fl oz/day;
data not shown) increased from day 30–120 for all
groups by gender, indicating normal intake for LF-0.6
and LF-1.0 groups when compared to the Control for
this time period (examples: females at day 30, 25.9–26.9
fl oz/day and day 120, 33.3–34.2 fl oz/day; males at day
30, 28.2–30.0 fl oz/day and day 120, 35.0–35.7 fl oz/day).
Intake for female participants by group was similar at all
time points assessed. Statistically significant group differ-
ences in intake were noted among males at days 180
(Control: 36.5 fl oz/day; LF-0.6: 31.9 fl /day; LF-1.0: 33.7
fl oz/day; Control vs LF-0.6, P < 0.05) and 275 only.
However, by day 180, mean reported study formula
intake began to decline in general for both male and fe-
male participants which could be expected as parents
and caregivers likely begin to offer complementary foods
to infants at approximately 4–6 months of age. Parent-
reported gassiness and fussiness were similar among
groups at all study time points (data not shown). Using
24-h recall, the amount of gas most commonly reported
was “slight amount” or “moderate amount” up to 180
days of age and “none at all” or “slight amount” by 275
and 365 days of age. Fussiness was most often character-
ized as “slightly fussy” or “not at all fussy” in all groups.
No significant group differences in mean (±SE) stool fre-
quency (number/day) were detected at any time point
assessed (Table 4). No group differences in mean (±SE)
stool consistency (with categories corresponding to 1 =
hard, 2 = formed, 3 = soft, 4 = unformed or seedy, 5 =
watery; Table 4) were detected at baseline. Significant
differences in stool consistency were detected between
Control and investigational formula groups from day 30
through 180. By category, the primary differences at
these study time points were more infants with a formed
and fewer infants with an unformed or seedy stool
consistency in the Control compared to LF-0.6 and LF-1.0
groups. The majority of infants in all groups from day 30–
365 were reported to have a soft stool consistency. There
were no significant differences among study formula
groups by day 275, possibly reflecting the increased
amount of complementary feeding in older children con-
suming less formula.
In the overall study population (all participants up to
365 days of age) no statistically significant group differ-
ences were detected for study formula discontinuation
either related to study formula (Control: 18, 12 %; LF-
0.6: 20, 12 %; LF-1.0: 17, 11 %) or not related to study
formula (Control: 50, 32 %; LF-0.6: 42, 26 %; LF-1.0: 49,
31 %). Of the 55 participants with formula-related dis-
continuation, formula intolerance as determined by the
study investigator was the most common reason (Con-
trol: 13; LF-0.6: 14; LF-1.0: 15) with fussiness (Control:
5; LF-0.6: 8; LF-1.0: 10) and gas (Control: 6; LF-0.6: 3;
LF-1.0: 6) as the most common symptoms. Parental de-
cision was the most common reason for discontinuation
not related to study formula (Control: 13; LF-0.6: 7; LF-
1.0: 19).
No group difference was detected in the number of
participants for whom at least one medically-confirmed
adverse event was reported (Control: 141, 92 %; LF-0.6:
154, 94 %; LF-1.0: 149; 94 %). There were no statistically
significant group differences detected in the overall inci-
dence of adverse events for the following systems: Body
as a Whole; Cardiovascular; Eyes, Ear, Nose and Throat;
Endocrine; Gastrointestinal (GI); Metabolic and Nutri-
tion; Musculoskeletal; Nervous System; Respiratory; and
Skin. Significantly fewer participants in the Control (6, 4
Table 2 Infant characteristics at study entry
Study Group
Control LF-0.6 LF-1.0
Total number of participants 154 164 158
Number of males/females 88/66 94/70 87/71
malesa
Weight (g) 3662.4 ± 45.3 3649.2 ± 43.8 3704.8 ± 45.5
Length (cm) 52.3 ± 0.2 52.5 ± 0.2 52.7 ± 0.2
Head circumference (cm) 36.2 ± 0.1 36.2 ± 0.1 36.3 ± 0.1
femalesa
Weight (g) 3575.5 ± 45.5 3505.0 ± 44.2 3560.6 ± 43.9
Length (cm) 51.9 ± 0.2 51.5 ± 0.2 52.0 ± 0.2
Head circumference (cm) 35.7 ± 0.1 35.5 ± 0.1 35.7 ± 0.1
aMean ± standard error (SE)
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Table 3 Weight, length, and head circumference growth rates from 14 days to 30, 60, 90, 120, 180, 275, and 365 days of age
Growth ratea
Gender Day Group (n) Weight (g/day) Length (cm/day) Head circumference (cm/day)
male 30 Control (81) 45.1 ± 1.4 0.15 ± 0.009 0.09 ± 0.004
LF-0.6 (92) 44.4 ± 1.3 0.14 ± 0.008 0.10 ± 0.004
LF-1.0 (81) 44.3 ± 1.4 0.16 ± 0.009 0.10 ± 0.004
60 Control (74) 39.0 ± 1.1 0.13 ± 0.004 0.07 ± 0.002
LF-0.6 (86) 38.5 ± 1.0 0.13 ± 0.003 0.08 ± 0.002
LF-1.0 (69) 39.6 ± 1.1 0.13 ± 0.004 0.07 ± 0.002
90 Control (69) 35.1 ± 0.9 0.12 ± 0.002 0.06 ± 0.001
LF-0.6 (82) 34.8 ± 0.8 0.12 ± 0.002 0.06 ± 0.001
LF-1.0 (67) 35.4 ± 0.9 0.12 ± 0.002 0.06 ± 0.001
120 Control (69) 31.8 ± 0.8 0.11 ± 0.002 0.06 ± 0.001
LF-0.6 (80) 31.8 ± 0.7 0.11 ± 0.002 0.06 ± 0.001
LF-1.0 (63) 31.9 ± 0.8 0.11 ± 0.002 0.06 ± 0.001
180 Control (66) 27.5 ± 0.6 0.10 ± 0.001 0.05 ± 0.001
LF-0.6 (78) 27.8 ± 0.6 0.09 ± 0.001 0.05 ± 0.001
LF-1.0 (60) 27.4 ± 0.7 0.09 ± 0.002 0.05 ± 0.001
275 Control (64) 22.5 ± 0.5 0.08 ± 0.001 0.04 ± 0.001
LF-0.6 (73) 22.7 ± 0.4 0.08 ± 0.001 0.04 ± 0.001
LF-1.0 (61) 22.3 ± 0.5 0.08 ± 0.001 0.04 ± 0.001
365 Control (62) 19.1 ± 0.4 0.07 ± 0.001 0.03 ± 0.000
LF-0.6 (68) 18.9 ± 0.3 0.07 ± 0.001 0.03 ± 0.000
LF-1.0 (61) 19.1 ± 0.4 0.07 ± 0.001 0.03 ± 0.000
female 30 Control (60) 38.6 ± 1.5 0.12 ± 0.011 0.08 ± 0.005
LF-0.6 (67) 35.7 ± 1.4 0.14 ± 0.010 0.08 ± 0.004
LF-1.0 (67) 37.1 ± 1.4 0.13 ± 0.010 0.08 ± 0.004
60 Control (54) 32.4 ± 1.0 0.12 ± 0.004 0.07 ± 0.002
LF-0.6 (60) 30.6 ± 0.9 0.12 ± 0.004 0.06 ± 0.002
LF-1.0 (59) 29.7 ± 0.9b 0.12 ± 0.004 0.06 ± 0.002
90 Control (50) 28.1 ± 0.8 0.11 ± 0.003 0.06 ± 0.001
LF-0.6 (58) 27.1 ± 0.8 0.10 ± 0.003 0.05 ± 0.001
LF-1.0 (59) 27.5 ± 0.8 0.11 ± 0.003 0.06 ± 0.001
120 Control (51) 26.2 ± 0.7 0.10 ± 0.002 0.05 ± 0.001
LF-0.6 (58) 25.4 ± 0.7 0.10 ± 0.002 0.05 ± 0.001
LF-1.0 (55) 25.5 ± 0.7 0.10 ± 0.002 0.05 ± 0.001
180 Control (47) 23.4 ± 0.6 0.09 ± 0.002 0.04 ± 0.001
LF-0.6 (57) 22.7 ± 0.5 0.09 ± 0.002 0.04 ± 0.001
LF-1.0 (54) 22.9 ± 0.5 0.09 ± 0.002 0.04 ± 0.001
275 Control (46) 19.7 ± 0.5 0.07 ± 0.001 0.03 ± 0.001
LF-0.6 (55) 19.4 ± 0.4 0.07 ± 0.001 0.03 ± 0.001
LF-1.0 (54) 19.5 ± 0.4 0.07 ± 0.001 0.03 ± 0.001
365 Control (44) 16.9 ± 0.4 0.07 ± 0.001 0.03 ± 0.000
LF-0.6 (53) 16.6 ± 0.4 0.06 ± 0.001 0.03 ± 0.000
LF-1.0 (54) 16.9 ± 0.3 0.07 ± 0.001 0.03 ± 0.000
aMean ± standard error (SE)
bSignificantly lower than Control, P < 0.05, one-tailed test
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Fig. 2 Mean achieved weight for male participants with World Health Organization (WHO) reference percentiles (3rd to 97th) through 12 months
(14 to 365 days) of age. Control, stars; LF-0.6, circles; LF-1.0, diamonds
Fig. 3 Mean achieved weight for female participants with World Health Organization (WHO) reference percentiles (3rd to 97th) through 12 months
(14 to 365 days) of age. Control, stars; LF-1.0, circles; LF-0.6, diamonds
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%) and LF-0.6 (7, 4 %) groups versus the LF-1.0 group
(17, 11 %; P < 0.05) experienced Urogenital system
events. Although no significant group differences were
detected for specific adverse events in this system, the
incidence of penile adhesion (Control: 2, 2 %; LF-0.6: 3,
3 %; LF-1.0: 8, 9 %), commonly associated with circumci-
sion in young male infants, appeared to drive the overall
statistical difference. Within the GI System, the medically-
confirmed incidence of diarrhea, constipation, emesis, or
gas was low with no significant group differences; however
gastroesophageal (GE) reflux (Control: 27, 18 %; LF-0.6:
24, 15 %; LF-1.0: 41, 26 %) was significantly lower in the
LF-0.6 versus the LF-1.0 group (P < 0.05). Within the Ner-
vous System the incidence of macrocephaly (defined as
head circumference >98th reference percentile; Control: 3,
2 %; LF-0.6: 0; LF-1.0: 0; P < 0.05) was low, albeit statisti-
cally significant. No associated underlying health condi-
tions were reported by study investigators for these
participants and all completed the study. No group
differences were detected in the incidence of allergy- or
infection-related adverse events; however, this study was
not powered to detect likely subtle differences in this
population of healthy term infants. A total of 41 partici-
pants (Control: 14, 9 %; LF-0.6: 13, 8 %; LF-1.0: 14, 9 %)
experienced serious adverse events (SAEs). With the ex-
ception of one SAE in the Control group in which the par-
ticipant was diagnosed with likely cow’s milk protein
intolerance, all SAEs were deemed unrelated to study for-
mulas as assessed by study physicians.
Discussion
Results of the current study demonstrate routine cow’s
milk-based formulas with bLf at 0.6 or 1.0 g/L are asso-
ciated with normal growth through 365 days of age.
With one exception for female weight growth rate in the
day 14–60 age range only, no statistically significant
group differences were observed for weight, length, or
head circumference growth rates from 14–365 days of
Table 4 Stool characteristics at 14, 30, 60, 90, 120, 180, 275, and 365 days of age
Stool frequency Stool consistency, n (%)
Age (days) Group (n) Mean ± SEa Overall P hard formed soft unformed or seedy watery Overall P
14 Control (154) 3.1 ± 0.2 0.774 2 (1) 9 (6) 75 (49) 62 (41) 5 (3) 0.092
LF-0.6 (164) 3.3 ± 0.2 0 (0) 4 (3) 71 (45) 77 (48) 7 (4)
LF-1.0 (158) 3.3 ± 0.2 2 (1) 6 (4) 77 (49) 65 (42) 6 (4)
30 Control (133) 2.4 ± 0.1 0.516 10 (8) 18 (14) 82 (62) 22 (17) 0 (0) <0.001†‡
LF-0.6 (152) 2.6 ± 0.1 0 (0) 2 (1) 76 (50) 64 (42) 10 (7)
LF-1.0 (141) 2.5 ± 0.1 1 (1) 6 (4) 66 (47) 59 (42) 8 (6)
60 Control (123) 1.9 ± 0.1 0.661 0 (0) 17 (14) 77 (65) 25 (21) 0 (0) <0.001†‡
LF-0.6 (141) 2.0 ± 0.1 0 (0) 1 (1) 77 (57) 51 (38) 7 (5)
LF-1.0 (123) 1.9 ± 0.1 0 (0) 1 (1) 65 (55) 45 (38) 8 (7)
90 Control (118) 2.1 ± 0.1 0.882 2 (2) 11 (9) 79 (68) 23 (20) 2 (2) <0.001†‡
LF-0.6 (137) 2.0 ± 0.1 0 (0) 2 (2) 76 (58) 44 (33) 10 (8)
LF-1.0 (119) 2.0 ± 0.1 0 (0) 1 (1) 78 (68) 33 (29) 3 (3)
120 Control (114) 2.0 ± 0.1 0.426 2 (2) 16 (15) 69 (64) 20 (19) 1 (1) <0.001†‡
LF-0.6 (135) 1.9 ± 0.1 0 (0) 4 (3) 81 (63) 40 (31) 4 (3)
LF-1.0 (113) 1.8 ± 0.1 0 (0) 3 (3) 76 (70) 27 (25) 3 (3)
180 Control (111) 2.0 ± 0.1 0.242 6 (5) 28 (25) 71 (63) 6 (5) 1 (1) <0.001†‡
LF-0.6 (134) 2.3 ± 0.1 1 (1) 18 (14) 91 (70) 20 (15) 0 (0)
LF-1.0 (113) 2.1 ± 0.1 1 (1) 8 (7) 88 (79) 15 (13) 0 (0)
275 Control (108) 2.2 ± 0.1 0.700 5 (5) 36 (33) 62 (57) 5 (5) 1 (1) 0.267
LF-0.6 (127) 2.1 ± 0.1 3 (2) 35 (28) 78 (62) 5 (4) 4 (3)
LF-1.0 (115) 2.3 ± 0.1 5 (4) 26 (23) 74 (65) 6 (5) 2 (2)
365 Control (94) 2.1 ± 0.1 0.599 6 (6) 33 (35) 47 (51) 6 (6) 1 (1) 0.352
LF-0.6 (107) 2.2 ± 0.1 4 (4) 29 (27) 65 (60) 9 (8) 1 (1)
LF-1.0 (98) 2.0 ± 0.1 4 (4) 36 (38) 47 (49) 2 (2) 7 (7)
aMean ± standard error (SE) stool frequency
†Control vs. LF-0.6 significantly different (P < 0.05)
‡Control vs. LF-1.0 significantly different (P < 0.05)
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age. In addition, mean achieved weight for males and fe-
males were within the 25th and 75th percentiles of the
WHO weight-for-age growth chart from 14–365 days of
age and no group differences for mean achieved weight,
length, or head circumference were detected. Healthy
growth and development have been previously demon-
strated in infants receiving bLf [7, 26], however, this is
the first large pediatric nutrition trial designed to evalu-
ate growth in which participants received infant formula
with concentrations of bLF that correspond to those re-
ported for mature human milk in conjunction with a
prebiotic blend of PDX and GOS.
In the current study, acceptance and tolerance of study
formulas were good. No differences in overall study dis-
continuation or study discontinuation due to study for-
mula were detected. No significant group differences
were detected in fussiness, gassiness, or mean stool fre-
quency at any measured time point. The majority of in-
fants in all groups from day 30–365 were reported to
have a soft stool consistency. However, significant differ-
ences in mean stool consistency were detected by day 30
and continued through day 180; more infants with a
formed and fewer infants with an unformed or seedy
stool consistency in the Control compared to the investi-
gational formula groups were the primary differences.
No group differences were observed by day 275, as
noted previously, likely reflecting the increased amount
of complementary feeding in older children consuming
less formula. Collecting a more complete dietary recall
after 120 days of age (vs formula intake only) could im-
prove our understanding of the relationship of infant
formula and use of complementary foods in feeding
practices over the first year of life. Though a current
study limitation, at least in evaluation of some secondary
outcomes through 365 days of age, this represents a po-
tential next step for future studies.
The primary long-chain polyunsaturated fatty acids
found in human milk, DHA and ARA, are always
present, albeit at various concentrations and ratios [22,
27, 28]. Previously published values for worldwide hu-
man milk DHA and ARA [29, 30] provided the founda-
tion for infant formulas with DHA and ARA (at ~0.3 %
and ~0.6 % of total fat, respectively), associated with vis-
ual and cognitive development in term infants [31–35]
and enhanced growth and neural development in pre-
term infants [36, 37]. Updated worldwide means for hu-
man milk DHA at 0.32 % (SD 0.21 %; median 0.26 %;
mode 0.20 %) and ARA at 0.47 % (SD 0.13 %; median
0.45 %; mode 0.50 %) of total fatty acids were published
in the most recent comprehensive, critical review of lit-
erature [22]. We previously evaluated routine, cow’s
milk-based formulas with adjusted ARA and demon-
strated they are well-tolerated, safe and promote normal
growth from 14–120 days of age [18]. In the current
study, routine cow’s milk-based formulas with bLf and
adjusted ARA were safe, well-tolerated, and associated
with normal growth when fed to healthy term infants
through 365 days of age.
The stool softening effect demonstrated with the PDX
and GOS prebiotic blend may potentially help address
occasional hard stools that could affect formula-fed in-
fants [38]. In healthy, term infants we previously re-
ported that use of routine formulas with a prebiotic
blend of PDX and GOS (4 g/L, 1:1 ratio) produced a
bifidogenic effect closer to breast milk [17] and softer
stools in healthy, term infants compared to formula
without PDX and GOS [16–19]. Similarly, Lf may also
effect change in the gastrointestinal microbiota. For ex-
ample, the ratio of fecal Bifidobacterium to Enterobacte-
riaceae and Clostridium increased in low-birth weight
infants receiving infant formula with bLf (1 g/L) [39]
and bLf promoted dose-dependent Bifidobacterium
growth in vitro [40]. A stronger bifidogenic effect has
also been described for pepsin hydrolysates of bLf, sug-
gesting the outcome of gastric digestion on Lf may ex-
tend to that found in human milk as well as infant
formula with bLf [41]. Based on modified stool
consistency observed in this and previous studies, fur-
ther exploration of potential synergistic effects of provid-
ing infant formulas with bLf and the PDX and GOS
blend on the infant fecal microbiota and other poten-
tially associated health outcomes may be warranted.
Conclusions
Routine intact cow’s milk protein infant formulas with
bLf at 0.6 and 1.0 g/L were associated with age-
appropriate growth throughout the first year of life. This
was the first large-scale pediatric nutrition trial in which
formulas used concentrations of bLf that are within the
range of Lf reported for mature human milk and in-
cluded the prebiotic blend of PDX and GOS. Compared
to infants who received the Control formula, infants
who received investigational formulas with the prebiotic
blend of PDX and GOS and bLf at 0.6 or 1.0 g/L experi-
enced a softer stooling pattern similar to that reported
in breastfed infants. Consequently, this study demon-
strated that routine infant formulas with bLf, a blend of
PDX and GOS, and adjusted ARA were safe, well-
tolerated, and associated with normal growth when fed
to healthy term infants throughout the first year of life.
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